Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1/2 1

Status

Unknown 19Recruiting 9Not yet recruiting 5Active not recruiting 4Completed 3

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 5Breast Neoplasms 4Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Locally Advanced Gastric Cancer 2Colorectal Neoplasms 2Cervical Cancer Metastatic 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Rare Tumour 1Non-squamous Non-small Cell Lung Cancer 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Laryngeal Neoplasms 1Esophageal Squamour Cell Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Chemotherapy 1Biliary Tract Neoplasms 1Advanced Triple Negative Breast Cancer 1Advanced Pancreatic Cancer 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 11tislelizumab 9apatinib 8regorafenib 6donafenib 6camrelizumab 5atezolizumab 4Immune Checkpoint Inhibitors 4Hepatectomy 4durvalumab 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2cabozantinib 2anlotinib 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × camrelizumab × Clear all
NCT07314372 2026-01-20

FAD-HCC-001

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Not yet recruiting
86 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07324473 2026-01-07

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

First Affiliated Hospital of Chongqing Medical University

Phase 2 Not yet recruiting
65 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07309419 2025-12-30

Cocktail-001

Shanghai Zhongshan Hospital

Phase 2/3 Not yet recruiting
222 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06546280 2024-08-09

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Zhujiang Hospital

Phase 2 Not yet recruiting
38 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06124001 2023-11-15

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

CNBG-Virogin Biotech (Shanghai) Ltd.

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡